Previous Article | Next Article 
J Virol, July 1998, p. 6146-6150, Vol. 72, No. 7
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Novel Gag-Pol Frameshift Site in Human
Immunodeficiency Virus Type 1 Variants Resistant to Protease
Inhibitors
Louise
Doyon,1
Catherine
Payant,2
Léa
Brakier-Gingras,2 and
Daniel
Lamarre1,*
Bio-Méga Research Division, Boehringer
Ingelheim (Canada) Ltd., Laval, Quebec, Canada H7S
2G5,1 and
Département de
Biochimie, Université de Montréal, Montréal, Quebec,
Canada H3C 3J72
Received 29 September 1997/Accepted 25 March 1998
 |
ABSTRACT |
Human immunodeficiency virus type 1 (HIV-1) variants resistant to
protease inhibitors have been shown to contain a mutation in the p1/p6
Gag precursor cleavage site. At the messenger RNA level, this mutation
generates a U UUU UUU sequence that is reminiscent of the U UUU UUA
sequence required for ribosomal frameshifting and Gag-Pol synthesis. To
test whether the p1/p6 cleavage site mutation was generating a novel
frameshift site, HIV sequences were inserted in translation vectors
containing a chloramphenicol acetyltransferase (CAT) reporter gene
requiring
1 frameshifting for expression. All sequences containing
the original HIV frameshift site supported the synthesis of CAT but
expression was increased 3- to 11-fold in the presence of the mutant
p1/p6 sequence. When the original frameshift site was abolished by
mutation, expression remained unchanged when using constructs
containing the mutant p1/p6 sequence, whereas it was decreased 2- to
4.5-fold when using wild-type p1/p6 constructs. Similarly, when
introduced into HIV molecular clones, the p1/p6 mutant sequence
supported Gag-Pol synthesis and protease activity in the absence of the
original frameshift site, indicating that this sequence could
also promote ribosomal frameshifting in virus-expressing cells.
 |
TEXT |
To overcome the antiviral effects of
protease inhibitors in culture or in vivo, human immunodeficiency virus
type 1 (HIV-1) accumulates mutations in its protease gene and in Gag
precursor cleavage sites (reviewed in reference 21).
Two cleavage sites were shown to be mutated in resistant variants: the
p1/p6 cleavage site (3, 6, 25) and the NC(p7)/p1 cleavage
site (6, 25). These mutations improve peptide hydrolysis by
the protease in vitro and improve polyprotein processing in virions
(6). In all mutants analyzed, the p1/p6 mutation involves an
L
F modification at the p1' position of the scissile bond
(6). In the DNA, this mutation is a C-to-T transition of the
first base of the leucine codon, replacing the wild-type AAT TTT CTT
sequence in this region with the AAT TTT TTT sequence (Fig.
1A). When this sequence is transcribed
into RNA, the resulting mutant stretch of nucleotides, AAU UUU UUU, is
quite reminiscent of the AAU UUU UUA sequence required for ribosomal
frameshifting and Gag-Pol synthesis (Fig. 1B) (13).
Interestingly, this mutant sequence is also located in close proximity
to the original frameshift site in HIV, which itself overlaps the p7/p1
cleavage site sequence in Gag (Fig. 1A). This therefore suggested not
only that the p1/p6 cleavage site mutation was improving the processing
of precursors at the protein level but also that the mutant sequence
could constitute a novel slippery site promoting ribosomal
frameshifting during mRNA translation.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 1.
Nucleic acid sequences of the p1/p6 cleavage site
mutation in HIV-1 protease inhibitor-resistant variants. (A) Variants
obtained in the presence of protease inhibitors were sequenced in the
p7/p1/p6 region, and DNA sequences were compared to that of the HIV-1
IIIB strain (5, 6, 17). The portion of the DNA sequence from
HIV-1 IIIB is shown in its entirety as well as the deduced amino acid
sequences (indicated in single-letter codes), read either in the Gag
frame (top) or in the Pol frame (bottom). The arrows indicate the
scissile bonds of the p7/p1 and p1/p6 cleavage sites. The sequences of
variants obtained in the presence of palinavir (2011.40 and
2011.nL.23), BILA 1906 BS (1906.33), and BILA 2185 BS (2185.37) are
shown, with sequence identity illustrated by a dash. All mutants
contain a C-to-T transition at the p1/p6 junction. (B) Transcribed into
RNA, the p7/p1/p6 sequence is predicted to give a stem-loop structure,
with the p7/p1 and p1/p6 potential slippery sites (underlined) lying on
either side. The dotted line shows a sequence possibly involved in
transient pairing with 18S rRNA (see the text).
|
|
In HIV, as in many other retroviruses (7, 9, 13, 14),
frameshifting is required to synthesize two polyproteins (Gag and
Gag-Pol in HIV) starting from the same initiation codon of an mRNA.
Translation of the HIV Gag terminates at the carboxy-terminal end of
the p6 protein, around codon 500 of the mRNA, whereas synthesis of
Gag-Pol requires a shift of the reading frame in the 5' direction (
1
shift) at the p7/p1 junction, around codon 432 of the mRNA (13). Translation of Gag-Pol then proceeds in this new
reading frame until a stop codon is reached, about 3,000 nucleotides
later. Ribosomal
1 frameshifting is a very controlled event requiring both a heptameric X XXY YYZ consensus slippery sequence (U UUU UUA in
HIV) and a downstream secondary RNA structure which causes the ribosome
to pause (a stem-loop in HIV; Fig. 1B) (4, 8, 9, 13). Under
optimal conditions, however, frameshifting is a rare event, occurring
only for 1 of 10 to 20 ribosomes. This controlled frequency ensures
that the synthesis of Gag and Gag-Pol occurs in the correct ratio,
which is required for optimal enzyme activation and virus assembly
(12, 18).
Since protease inhibitor-resistant variants have impaired protease
activity due to mutations (5, 10, 20), they could benefit
from an increased level of Gag-Pol frameshifting that would increase
the level of enzyme proteins in the virus. To determine if the p1/p6
mutation observed in resistant HIV was indeed creating a novel
frameshift site, in vitro translation vectors were constructed. A
plasmid construct in which a 93-bp DNA sequence encompassing the HIV
p7/p1/p6 region was inserted at the beginning of the chloramphenicol acetyltransferase (CAT) coding sequence of pHC(
1), a derivative of
plasmid bluescript SK
(Stratagene), was made (Fig.
2). The HIV sequence encodes the original
frameshift site (site a), the putative stem-loop structure, and the
p1/p6 cleavage site sequence (site b). Expression of the CAT reporter
gene is driven by a T7 promoter, and requires a
1 frameshift in the
HIV sequence, in the absence of which an in-frame stop codon terminates
translation at codon 45 of the CAT coding sequence. Construct pHC(
1)
has the wild-type HIV sequence at the beginning of the CAT gene
sequence, while construct pHCF(
1) has an HIV sequence in which a
C-to-T transition was inserted at the p1/p6 junction (site b). As
controls, constructs in which no frameshift was required for CAT
expression were used. These constructs [pHC(0) and pHCF(0)] contain
an additional base pair four codons downstream of the putative second
frameshift site, at site c, which renders the HIV gene sequence in
frame with the CAT gene sequence. All constructs were linearized at the
unique BamHI site located 3' of the CAT coding sequence, and
1 µg of DNA was used for in vitro RNA transcription by the T7 RNA
polymerase. RNA was then translated in a rabbit reticulocyte lysate. In
assays using [35S]methionine, messengers from both pHC(0)
and pHCF(0) constructs were efficiently translated into a protein whose
molecular mass, 28 kDa, corresponded to the expected molecular mass of
the HIV-CAT fusion protein. In contrast, constructs pHC(
1) and
pHCF(
1), requiring a
1 frameshift for expression, gave only weak
bands of 28 kDa, as expected (data not shown).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 2.
Construction of a CAT expression vector for in vitro
translation. A 93-bp DNA sequence encompassing the HIV p7/p1/p6 region
was inserted in the beginning of the coding sequence of a CAT reporter
gene which is under the control of a T7 promoter. The HIV and CAT
sequences are not in the same reading frame, so a 1 frameshift in the
HIV sequence is required to produce the CAT protein. The inserted HIV
sequence is shown in boldface, with the original frameshift site (site
a), the p1/p6 junction (site b), and the region in which an additional
base pair was added to make the HIV and CAT sequences in frame (site c)
underlined. The sequences of sites a, b, and c of all constructs used
in this study are indicated in the bottom half of the figure, with
added or modified nucleotides underlined. Apart from these three sites,
all constructs were identical and were used in similar in vitro
transcription and translation experiments.
|
|
To quantitate the frequency of frameshifting generated with these
constructs, the level of CAT expression was assessed by an
immunological CAT enzyme-linked immunosorbent assay (ELISA). As shown
in Table 1, the wild-type HIV sequence
[pHC(
1)] gave a frameshift of from 5 to 12.9% in rabbit
reticulocyte lysates with respect to the in-frame pHC(0) construct, a
result similar to that already reported for this sequence (19,
24). The presence of a mutation at the p1/p6 junction in
pHCF(
1) clones, however, gave a frameshift of from 15 to 30% with
respect to the in-frame control constructs [pHCF(0)], an
approximately threefold increase compared to that for the wild-type HIV
sequence. Both capped (experiment 3) and uncapped (experiments 1 and 2)
RNAs were assayed in these experiments, with no significant difference
found. CAT levels determined by the method of chloramphenicol
acetylation (CAT assays) (22) also gave results comparable
to those in Table 1 (data not shown). Therefore, these experiments
suggest that the mutation in the HIV p1/p6 cleavage site sequence was
enhancing the extent of ribosomal frameshifting in vitro.
The effect of the p1/p6 mutation could be due to the generation of a
novel frameshift site in the pHCF(
1) sequence. However, there is a
possibility that the increase in frameshifting could also be due to the
presence of novel or more complex secondary structures in the mutant
mRNA. To distinguish between these two possibilities, constructs
pHC(
1)k/o and pHCF(
1)k/o were generated (Fig. 2). In these
constructs, the original T TTT TTA slippery sequence at site a was
replaced by site-directed mutagenesis with the nonslippery sequence T
CCC GCG, thereby preventing frameshifting at this site. This mutation
also generated a novel SacII restriction site in the DNA,
used for easy screening. Table 1 shows the levels of CAT expression
found when comparing these pHC(
1)k/o and pHCF(
1)k/o constructs with
their parental pHC(
1) and pHCF(
1) constructs. Abolishing the
original frameshift site in pHC(
1)k/o reduced CAT expression by 2.6- to 4.5-fold with respect to the wild-type HIV sequence. Interestingly,
residual CAT levels were consistently observed with pHC(
1)k/o
constructs, suggesting that ribosomal slippage at the original
frameshift site was not the only mechanism generating CAT expression in
this system. In assays using mutant pHCF(
1) and pHCF(
1)k/o
constructs on the other hand, there was no significant difference in
CAT expression (1.1- to 1.3-fold reduction) suggesting that the p1/p6
cleavage site mutation could compensate for the change in the original
frameshift site. Again, uncapped RNAs (experiment 1), capped RNAs
(experiments 2 and 3), and CAT assays (data not shown) gave similar
results. Since ribosomal slippage still efficiently occurs in the
absence of the original frameshift site in pHCF(
1)k/o constructs, the
p1/p6 mutation must therefore generate a novel frameshift site.
To determine the relevance of these results for virions, HIV molecular
clones were constructed (Fig. 3A). These
clones, derived from a modified pNL4.3 (1) plasmid called
2.12 (6), contained all the NL4.3 HIV genetic information
except for a 930-bp sequence taken from the HIV-I IIIB strain. This
930-bp sequence contained part of the p7 gene, the entire p1 and p6
genes, and 3' sequences leading into the reverse transcriptase gene
(6). Clone wt contained all wild-type HIV-1 sequences,
whereas site-directed mutagenesis was conducted to introduce the C-to-T
transition at the p1/p6 junction of clone wtFF. Mutagenesis was also
carried out to modify the original frameshift site from T TTT TTA to T
CCC GCG in constructs wtk/o and wtFFk/o. Proviral DNA (2 µg) from
these clones was transfected in human embryonic kidney cell line 293 to
produce virions, as described previously (6). Western blot
analysis of recovered virions showed that whereas both wt and wtFF
virions produce mature p24 protein by processing the
p55gag precursor, wtk/o viruses, in which the
original frameshift site was abolished by mutation, produce very low
levels of the p24 protein (Fig. 3B). These wtk/o viruses did, however,
contain high levels of precursor polyprotein
p55gag, suggesting that processing by an active
protease, which requires ribosomal frameshifting to synthesize Gag-Pol,
was deficient in the absence of a functional slippery sequence. In
contrast, wtFFk/o viruses containing a C-to-T mutation at the p1/p6
junction produced significant amounts of mature p24 protein, although
the original slippery sequence had been abolished, indicating that
Gag-Pol frameshifting had occurred in these viruses. In all wtFFk/o
clones examined, large amounts of unprocessed
p55gag precursors were detected, suggesting that
protease activity, although obviously present in these viruses, must be
suboptimal. An analysis of p6 protein expression by Western blotting
confirmed the presence of active protease in wtFFk/o clones but not in
wtk/o clones (Fig. 3B). These results therefore indicate that the
C-to-T mutation at the p1/p6 junction gives rise to a functional
frameshift site in HIV, in the absence of the original slippery
sequence.

View larger version (36K):
[in this window]
[in a new window]
|
FIG. 3.
Construction and analysis of HIV frameshift mutant
molecular clones. (A) A 930-bp DNA fragment containing part of the p7
gene, the entire p1 gene, and 3' sequences leading into the reverse
transcriptase gene from HIV-1 strain IIIB was inserted between the
unique ApaI (A) and BST1107 (B) restriction sites of a
modified NL4.3 vector called 2.12 to generate clone wt. Site-directed
mutagenesis was then used as described previously (11) to
introduce the p1/p6 cleavage site mutation in clone wtFF and to abolish
the original frameshift site in clones wtk/o and wtFFk/o. The original
frameshift site is represented by a solid box, the abolished frameshift
site is represented by an open box, the wild-type p1/p6 cleavage site
is also represented by a solid box, and the mutated p1/p6 cleavage site
is represented by a shaded box. (B) Viral particles harvested upon
transfection of molecular clones were analyzed by Western blotting
using monoclonal antibodies directed either against the p24 protein
(clone 39/5.1.23; ID Labs Inc.) or the p6 protein (23).
Proteins of 55, 41, 24, and 6 kDa representing the
p55gag and p41 precursors and the mature p24 and
p6 proteins, respectively, were detected. Two independent wtk/o clones
and four independent wtFFk/o clones are shown. Immune reactivity was
detected by a chemiluminescent substrate detection assay. The
infectivities of viruses, determined by infection of C8166 cells with
transfection supernatants, are shown as positive (+) or negative ( )
at the bottom of the figure.
|
|
Surprisingly, although Gag-Pol synthesis seemed possible in wtFFk/o
viruses and high levels of mature p24 and p6 proteins were produced in
these mutant viruses, no productive infection of T cells could be
obtained. Indeed, 10 days following infection of T-cell line C8166 with
wtFFk/o virus, no p24 protein could be detected in culture supernatants
by a sensitive ELISA and no cytopathic effect could be observed (Fig.
3B, bottom). This lack of infectivity could be due to the mutations
introduced to abolish the original frameshift site.
Finally, to unambiguously demonstrate that Gag-Pol synthesis had
occurred in wtFFk/o viruses and to confirm the presence of an active
protease in these mutants, proviral DNA was transfected in the presence
of the protease inhibitor palinavir (15) (Fig. 4). High concentrations of this protease
inhibitor should block all protease activity and lead to the
accumulation of unprocessed precursors p55gag
and p160gag-pol in virions (15).
Figure 4 shows that in the presence of 10 µM palinavir, wt viruses
indeed did not contain mature p24 protein and that there was an
accumulation of the polyprotein precursors p55gag and p160gag-pol
due to inactivation of the protease. Quantification of precursor bands
by density integration indicated that the Gag-Pol/Gag ratio in these
viruses is 0.13. Similar results were obtained with wtFF viruses, where
there are about 10 times more Gag than Gag-Pol precursors (ratio of
0.10). In wtk/o viruses, the very low level of mature p24 protein
observed previously disappeared in the presence of palinavir, and there
was also a slight accumulation of the p160gag-pol precursor, giving a Gag-Pol/Gag
ratio of 0.02, about sixfold lower than that observed for wt viruses.
In wtFFk/o viruses, p24 production was also completely blocked by the
presence of palinavir and significant levels of the
p160gag-pol precursor were observed. The
Gag-Pol/Gag ratio was estimated to be 0.08 for these mutant viruses,
about fourfold higher than that observed for wtk/o viruses. Therefore,
Gag-Pol synthesis does occur quite efficiently in wtFFk/o viruses in
the absence of the original slippery sequence.

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 4.
Blocking of protease activity in mutant viral clones
leads to the accumulation of polyprotein precursors. Viral particles
were produced in the presence of the protease inhibitor palinavir (10 µM) and then harvested and analyzed by Western blotting using an
anti-p24 monoclonal antibody. Proteins of 24, 55, and 160 kDa,
representing the mature p24 protein and the
p55gag and p160gag-pol
precursors, respectively, were detected. Longer exposure was required
for efficient p160gag-pol detection (bottom
panel). Gag-Pol/Gag ratios were estimated by comparing results obtained
from density integration of the 160- and 55-kDa bands.
|
|
These results therefore demonstrate that the U UUU UUU p1/p6 mutant
sequence found in HIV protease inhibitor-resistant variants can promote
ribosomal frameshifting both in vitro and in virus-expressing cells.
This is somewhat surprising because although the mutant sequence does
contain a consensus slippery heptamer, the latter is not in close
proximity to any 3' secondary structure, as determined by RNA
substructure search analysis (data not shown). The major function of
secondary structures is to cause the ribosome to pause, a process
during which frameshifting is thought to be more likely to occur
(8, 9). Two mechanisms could explain how frameshifting could
occur in the absence of 3' secondary structures. First, as the mutant
p1/p6 sequence is a stretch of seven consecutive U's, it is considered
superslippery (2, 24) and may not require ribosomal pausing
at all for frameshifting. Second, frameshifting could occur following
5' base pairing between viral and ribosomal RNAs, a
frameshift-enhancing mechanism already described for the Escherichia coli dnax gene (16). Interestingly,
analysis of mRNA sequences around the HIV p1/p6 junction reveals 5'
sequences that could pair with eukaryotic small-unit rRNA (bases 2113 to 2117 in the mRNA [Fig. 1B] and bases 1115 to 1119 in the 18S
rRNA). Experiments using constructs in which both the original
frameshift site and 5' flanking sequences are altered by mutagenesis
could give more insight into these possibilities.
 |
ACKNOWLEDGMENTS |
The M35/2F8 anti-p6 monoclonal antibody (23) was a
generous gift from M. G. Samgadharan (Advanced BioScience
Laboratories Inc., Kensington, Md.). We thank M. G. Cordingley for
critical review of the manuscript.
L.D. is a recipient of a University-Industry fellowship award from the
Medical Research Council of Canada.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Bio-Méga
Research Division, Boehringer Ingelheim (Canada) Ltd., 2100 Cunard,
Laval, Quebec, Canada H7S 2G5. Phone: (514) 682-4640. Fax: (514)
682-8434. E-mail:
dlamarre{at}bio-mega.boehringer-ingelheim.ca.
 |
REFERENCES |
| 1.
|
Adachi, A.,
H. E. Gendelman,
S. Koenig,
T. Folks,
R. Willey,
A. Rabson, and M. A. Martin.
1986.
Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone.
J. Virol.
59:284-291[Abstract/Free Full Text].
|
| 2.
|
Brierly, I., and A. J. Jenner.
1992.
Mutational analysis of the "slippery-sequence" component of a coronavirus ribosomal frameshifting signal.
J. Mol. Biol.
227:463-479[Medline].
|
| 3.
|
Carrillo, A.,
H. Sham,
D. Norbeck,
D. Kempf,
W. Kohlbrenner,
J. Plattner,
J. Leonard, and A. Molla.
1997.
Selection and analysis of HIV-1 variants with increased resistance to ABT-378, a novel protease inhibitor, abstr. 462.
In
Abstracts of the Fourth Conference on Retroviruses and Opportunistic Infections 1997. Infectious Diseases Society of America, Washington. D.C.
|
| 4.
|
Chamorro, M.,
N. Parkin, and H. E. Varmus.
1992.
An RNA pseudoknot and an optimal heptameric shift site are required for highly efficient ribosomal frameshifting on a retroviral messenger RNA.
Proc. Natl. Acad. Sci. USA
89:713-717[Abstract/Free Full Text].
|
| 5.
|
Croteau, G.,
L. Doyon,
D. Thibeault,
G. McKercher,
L. Pilote, and D. Lamarre.
1997.
Impaired fitness of human immunodeficiency virus type 1 variants with high-level resistance to protease inhibitors.
J. Virol.
71:1089-1096[Abstract].
|
| 6.
|
Doyon, L.,
G. Croteau,
D. Thibeault,
F. Poulin,
L. Pilote, and D. Lamarre.
1996.
Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.
J. Virol.
70:3763-3769[Abstract].
|
| 7.
|
Farabaugh, P. J.
1993.
Alternative readings of the genetic code.
Cell
74:591-596[Medline].
|
| 8.
|
Farabaugh, P. J.
1996.
Programmed translational frameshifting.
Annu. Rev. Genet.
30:507-528[Medline].
|
| 9.
|
Gesteland, R. F., and J. F. Atkins.
1996.
Recoding: dynamic reprogramming of translation.
Annu. Rev. Biochem.
65:741-768[Medline].
|
| 10.
|
Gulnik, S. V.,
L. I. Suvorov,
B. Liu,
B. Yu,
B. Anderson,
H. Mitsuya, and J. W. Erickson.
1995.
Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure.
Biochemistry
34:9282-9287[Medline].
|
| 11.
|
Higuchi, R.,
B. Krummel, and R. K. Saiki.
1988.
A general method of in vitro preparation and specific mutagenesis of DNA fragments: study of protein and DNA interaction.
Nucleic Acids Res.
16:7351-7367[Abstract/Free Full Text].
|
| 12.
|
Hunter, E.
1994.
Macromolecular interactions in the assembly of HIV and other retroviruses.
Semin. Virol.
5:71-83.
|
| 13.
|
Jacks, T.,
M. D. Power,
F. R. Masiarz,
P. A. Luciw,
P. J. Barr, and H. E. Varmus.
1988.
Characterization of ribosomal frameshifting in HIV-1 gag-pol expression.
Nature
331:280-283[Medline].
|
| 14.
|
Jacks, T.,
H. D. Madhani,
F. R. Masiarz, and H. E. Varmus.
1988.
Signals for ribosomal frameshifting in the Rous sarcoma virus gag-pol region.
Cell
55:447-458[Medline].
|
| 15.
|
Lamarre, D.,
G. Croteau,
E. Wardrop,
L. Bourgon,
D. Thibeault,
C. Clouette,
M. Vaillancourt,
E. Cohen,
C. Pargellis,
C. Yoakim, and P. C. Anderson.
1997.
Antiviral properties of palinavir, a potent inhibitor of the human immunodeficiency virus type 1 protease.
Antimicrob. Agents Chemother.
41:965-971[Abstract].
|
| 16.
|
Larsen, B.,
N. M. Wills,
R. F. Gesteland, and J. F. Atkins.
1994.
rRNA-mRNA base pairing stimulates a programmed 1 ribosomal frameshift.
J. Bacteriol.
176:6842-6851[Abstract/Free Full Text].
|
| 17.
|
Myers, G.,
B. Korber,
B. Foley,
K. T. Jeang,
J. W. Mellors, and S. Wain-Hobson.
1996.
In
Human retroviruses and AIDS: a compilation and analysis of nucleic acid and amino acid sequences.
Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, N.Mex.
|
| 18.
|
Park, J., and C. D. Morrow.
1991.
Overexpression of the gag-pol precursor from human immunodeficiency virus type 1 proviral genomes results in efficient proteolytic processing in the absence of virion production.
J. Virol.
65:5111-5117[Abstract/Free Full Text].
|
| 19.
|
Parkin, N. T.,
M. Chamorro, and H. E. Varmus.
1992.
Human immunodeficiency virus type 1 gag-pol frameshifting is dependent on downstream mRNA secondary structure: demonstration by expression in vivo.
J. Virol.
66:5147-5151[Abstract/Free Full Text].
|
| 20.
|
Pazhanisamy, S.,
M. Stuver,
A. B. Cullinan,
N. Margolin,
B. G. Rao, and D. J. Livingston.
1996.
Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants.
J. Biol. Chem.
271:17979-17985[Abstract/Free Full Text].
|
| 21.
|
Schinazi, R. F.,
B. A. Larder, and J. W. F. Mellors.
1997.
Mutations in retroviral genes associated with drug resistance.
Int. Antivir. News
5:129-142.
|
| 22.
|
Seed, B., and J. Y. Sheen.
1988.
A simple phase-extraction assay for chloramphenicol acetyletransferase activity.
Gene
67:271-277[Medline].
|
| 23.
|
Veronese, F.,
R. Rahman,
T. D. Copeland,
S. Oroszlan,
R. C. Gallo, and M. G. Sarngadharan.
1987.
Immunological and chemical analysis of p6, the carboxyl-terminal fragment of HIV p15.
AIDS Res. Hum. Retroviruses
3:253-264[Medline].
|
| 24.
|
Wilson, W.,
M. Braddock,
S. E. Adams,
P. D. Rathjen,
S. M. Kingsman, and A. J. Kingsman.
1988.
HIV expression strategies: ribosomal frameshifting is directed by a short sequence in both mammalian and yeast systems.
Cell
55:1159-1169[Medline].
|
| 25.
|
Zhang, Y.-M.,
H. Imamichi,
T. Imamichi,
H. C. Lane,
J. Falloon,
M. B. Vasudevachari, and N. P. Salzman.
1997.
Drug resistance during Indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.
J. Virol.
71:6662-6670[Abstract].
|
J Virol, July 1998, p. 6146-6150, Vol. 72, No. 7
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Ludwig, C., Leiherer, A., Wagner, R.
(2008). Importance of Protease Cleavage Sites within and Flanking Human Immunodeficiency Virus Type 1 Transframe Protein p6* for Spatiotemporal Regulation of Protease Activation. J. Virol.
82: 4573-4584
[Abstract]
[Full Text]
-
Girnary, R., King, L., Robinson, L., Elston, R., Brierley, I.
(2007). Structure-function analysis of the ribosomal frameshifting signal of two human immunodeficiency virus type 1 isolates with increased resistance to viral protease inhibitors. J. Gen. Virol.
88: 226-235
[Abstract]
[Full Text]
-
Dulude, D., Baril, M., Brakier-Gingras, L.
(2002). Characterization of the frameshift stimulatory signal controlling a programmed -1 ribosomal frameshift in the human immunodeficiency virus type 1. Nucleic Acids Res
30: 5094-5102
[Abstract]
[Full Text]
-
Dinman, J. D., Richter, S., Plant, E. P., Taylor, R. C., Hammell, A. B., Rana, T. M.
(2002). The frameshift signal of HIV-1 involves a potential intramolecular triplex RNA structure. Proc. Natl. Acad. Sci. USA
99: 5331-5336
[Abstract]
[Full Text]
-
Dauber, D. S., Ziermann, R., Parkin, N., Maly, D. J., Mahrus, S., Harris, J. L., Ellman, J. A., Petropoulos, C., Craik, C. S.
(2002). Altered Substrate Specificity of Drug-Resistant Human Immunodeficiency Virus Type 1 Protease. J. Virol.
76: 1359-1368
[Abstract]
[Full Text]
-
Beck, Z. Q., Lin, Y.-C., Elder, J. H.
(2001). Molecular Basis for the Relative Substrate Specificity of Human Immunodeficiency Virus Type 1 and Feline Immunodeficiency Virus Proteases. J. Virol.
75: 9458-9469
[Abstract]
[Full Text]
-
Ikuta, K., Suzuki, S., Horikoshi, H., Mukai, T., Luftig, R. B.
(2000). Positive and Negative Aspects of the Human Immunodeficiency Virus Protease: Development of Inhibitors versus Its Role in AIDS Pathogenesis. Microbiol. Mol. Biol. Rev.
64: 725-745
[Abstract]
[Full Text]
-
Gong, Y.-F., Robinson, B. S., Rose, R. E., Deminie, C., Spicer, T. P., Stock, D., Colonno, R. J., Lin, P.-f.
(2000). In Vitro Resistance Profile of the Human Immunodeficiency Virus Type 1 Protease Inhibitor BMS-232632. Antimicrob. Agents Chemother.
44: 2319-2326
[Abstract]
[Full Text]